874821-67-7

Usage

Uses

Used in Pharmaceutical Research:
(5-methyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE) is used as a building block for the synthesis of various pharmaceuticals due to its functional groups and reactivity. It plays a crucial role in the development of new drugs and therapeutic agents.
Used in Agrochemical Synthesis:
In the agrochemical industry, (5-methyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE) is used as a building block for the synthesis of various agrochemicals, contributing to the development of new pesticides and other agricultural products.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
(5-methyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE) is utilized as a chiral auxiliary in asymmetric synthesis, which is essential for the production of enantiomerically pure compounds. This application is vital in the pharmaceutical industry, where the stereochemistry of a drug can significantly impact its efficacy and safety.
Used in Antimicrobial and Antifungal Applications:
(5-methyl-1,3-oxazol-4-yl)methanol(SALTDATA: FREE) has been studied for its potential antimicrobial and antifungal properties, making it a promising compound for the development of new drugs and antimicrobial agents to combat resistant infections and fungal diseases.

Upstream product

• 32968-44-8 5-Methyl-4-oxazolcarbonsaeure-ethylester 
• 41172-57-0 5-Methyloxazol-4-carbonsaeure-methylester 

Downstream Products

• 956118-40-4 C₅H₅NO₂ 
• 1096163-97-1 (E)-2-(3,4-dimethoxystyryl)-5-methyloxazole-4-carbaldehyde 

Relevant academic research and scientific papers

Synthesis and evaluation of a novel series of 2,7-substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives as selective peroxisome proliferator-activated receptor γ partial agonists

A novel series of 7-substituted-2-[3-(2-furyl)acryloyl]-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline derivatives were synthesized to clarify structure–activity relationships for peroxisome proliferator-activated receptor γ (PPARγ) partial agonist activity

Optimization of Triarylpyridinone Inhibitors of the Main Protease of SARS-CoV-2 to Low-Nanomolar Antiviral Potency

Non-covalent inhibitors of the main protease (Mpro) of SARS-CoV-2 having a pyridinone core were previously reported with IC50 values as low as 0.018 μM for inhibition of enzymatic activity and EC50 values as low as 0.8 μM for inhibition of viral replication in Vero E6 cells. The series has now been further advanced by consideration of placement of substituted five-membered-ring heterocycles in the S4 pocket of Mpro and N-methylation of a uracil ring. Free energy perturbation calculations provided guidance on the choice of the heterocycles, and protein crystallography confirmed the desired S4 placement. Here we report inhibitors with EC50 values as low as 0.080 μM, while remdesivir yields values of 0.5-2 μM in side-by-side testing with infectious SARS-CoV-2. A key factor in the improvement is enhanced cell permeability, as reflected in PAMPA measurements. Compounds 19 and 21 are particularly promising as potential therapies for COVID-19, featuring IC50 values of 0.044-0.061 μM, EC50 values of ca. 0.1 μM, good aqueous solubility, and no cytotoxicity.

Expanding the chemical space of sp 3-enriched 4,5-disubstituted oxazoles via synthesis of novel building blocks

[Figure not available: see fulltext.] An efficient approach to the preparation of novel sp3-enriched 4,5-disubstituted oxazoles bearing a functional group at the C-4 position is described. The method commenced with synthesis of ethyl oxazole-4-carboxylates (13 examples, 63–99% yield), with subsequent function insertion to the heterocyclic core by late-stage functional group transformation. The LiBH4-mediated reduction of ethyl oxazole-4-carboxylates was the only method which could be optimized at multigram scale (up to 40 g), and its scope was demonstrated by preparation of 13 alcohols with (cyclo)alkyl, fluoroalkyl, or N-Boc-aminoalkyl moiety at the C-5 position (47–89% yield). The utility of these key intermediates was demonstrated by the preparation of chlorides (13 examples, 90–99% yield), azides (13 examples, 83–99% yield), amines (13 examples, 80–98% yield), and sulfonyl chlorides (4 examples, 68–97% yield) – advanced building blocks for synthetic and medicinal chemistry.

Method of coupling, and the coupling method using the aromatic group-substituted heterocyclic compound

Provided is an easy method (coupling method) capable of easily synthesizing a compound group in which aromatic molecules and aromatic molecules are coupled, a compound group in which aromatic molecules and alkene molecules are coupled, and the like without producing halogen waste and without the need to use scarce and expensive palladium. A compound (A) shown by general formula (A): Ar-H and a compound (B1) shown by general formula (B1): RaOCO-Ar', a compound (B2) shown by general formula (B2): RbCH=C(Ar")2, or a compound (B3) shown by general formula (B3): RcOCOCH=C(Ar")2 are reacted in the presence of a nickel compound.

C-H alkenylation of azoles with enols and esters by nickel catalysis

Rather u(Ni)que: Two new C-H alkenylation reactions, that is C-H/Ci￡O alkenylation and decarbonylative C-H alkenylation, of azoles are uniquely catalyzed by Ni/dcype. These azole alkenylation reactions are successfully applied to the convergent formal synthesis of siphonazoleB.

INTEGRASE INHIBITORS 3

The present invention provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. Compounds of formula (I) are also provided.